SK bioscience

본문바로가기

사이트맵 닫기

PR

SK bioscience company news updates

Media Zoom

SK Bioscience to invest $1.7 billion until 2027 with new growth strategy

2023.04.27
SK Bioscience chief says unlikely China will source vaccines from it, Financial Times reports

2023.01.09
Korean jab maker scouts Asean links

2022.12.17
SKYCovione, a self-assembled nanoparticle vaccine

2022.12.16
VIDEO: A Peek at SK Bioscience´s Covid-19 Vaccine Laboratory in South Korea

2022.12.14
SK Bioscience, 1st Korean biopharmaceutical firm to publish TCFD report

2022.12.06
SK bioscience plans global expansion push focused on vaccine manufacturing, gene therapy and more

2022.11.03
SK Bioscience aims to address vaccine inequality through global partnership

2022.10.21
Korea´s 1st homegrown COVID-19 vaccine maker underlines global partnership

2022.10.03
[Korean Vaccine No. 1] ‘Lead by Example’ CEO Ahn Jae-yong, ‘SKYCovione’ as Fourth Vaccination

2022.09.19
South Korea approves homegrown COVID-19 vaccine for booster shots

2022.09.18
‘Developing homegrown Covid-19 vaccine was not an easy decision’

2022.09.06